Global Heatstroke Treatment Market

Heatstroke Treatment Comprehensive Study by Type (Exertional Heat Stroke, Non-Exertional Heat Stroke), Drugs (Dantrolene, Midazolam, Clonidine, Meperidine, Others), Route of Administration (Oral, Parenteral), End-users (Hospitals, Homecare, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Diagnosis (Rectal Temperature, Blood Test, Urine Test, Muscle Function Test, Others) Players and Region - Global Market Outlook to 2029

Heatstroke Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Heatstroke Treatment
Heatstroke is the most serious form of heat injury and is considered a medical emergency. It can kill or cause damage to the brain and other internal organs. It often occurs as a progression from milder heat-related illnesses such as heat cramps, heat syncope (fainting), and heat exhaustion. The main aim of the heatstroke treatment is to lower the patient’s temperature and prevent further damage. The medications used in the treatment involves antihistamines, diet pills, diuretics, sedatives, tranquilizers, stimulants, seizure medications (anticonvulsants), heart and blood pressure medications such as beta-blockers and vasoconstrictors, and medications for psychiatric illnesses such as antidepressants and antipsychotics.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Heatstroke Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Mankind Pharma (India), Eagle Pharmaceuticals, Inc. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Medisim (United States), Takeda Pharmaceutical Company Limited (Japan), Novartis International AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services, Inc (United States), Abbott (United States) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are ALLERGAN (Ireland) and Sun Pharmaceutical Industries Ltd (India).

Segmentation Overview
AMA Research has segmented the market of Global Heatstroke Treatment market by Type (Exertional Heat Stroke and Non-Exertional Heat Stroke) and Region.



On the basis of geography, the market of Heatstroke Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Dantrolene will boost the Heatstroke Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Heatstroke Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Heatstroke Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Heatstroke Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Rectal Temperature will boost the Heatstroke Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Number of Online Pharmacies and Rise in the Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Heatstroke among People and Rising Number of Hospitals and Diagnostic Centres

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects of the Medications used for Treatment

Opportunities:
Growth in the Healthcare Industry Worldwide and Increased Healthcare Infrastructure in Developing Countries

Market Leaders and their expansionary development strategies
In November 2019, Eagle Pharmaceuticals, Inc. announced provided an update on the Company’s program for RYANODEX (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”). Eagle is investigating RYANODEX for EHS in addition to current standard of care, which is comprised of body cooling and supportive measures.
In September 2019, Otsuka Pharmaceutical Co., Ltd. has entered into a cooperative agreement with Niigata Prefecture, aiming to promote health and wellbeing with the objective of extending healthy life expectancy for Niigata Prefecture residents.


Key Target Audience
Heatstroke Treatment Providers, Research Professionals, Emerging Companies and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Exertional Heat Stroke
  • Non-Exertional Heat Stroke
By Drugs
  • Dantrolene
  • Midazolam
  • Clonidine
  • Meperidine
  • Others

By Route of Administration
  • Oral
  • Parenteral

By End-users
  • Hospitals
  • Homecare
  • Specialty Clinics

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Diagnosis
  • Rectal Temperature
  • Blood Test
  • Urine Test
  • Muscle Function Test
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Heatstroke among People
      • 3.2.2. Rising Number of Hospitals and Diagnostic Centres
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Number of Online Pharmacies
      • 3.4.2. Rise in the Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Heatstroke Treatment, by Type, Drugs, Route of Administration, End-users, Distribution Channel, Diagnosis and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Heatstroke Treatment (Value)
      • 5.2.1. Global Heatstroke Treatment by: Type (Value)
        • 5.2.1.1. Exertional Heat Stroke
        • 5.2.1.2. Non-Exertional Heat Stroke
      • 5.2.2. Global Heatstroke Treatment by: Drugs (Value)
        • 5.2.2.1. Dantrolene
        • 5.2.2.2. Midazolam
        • 5.2.2.3. Clonidine
        • 5.2.2.4. Meperidine
        • 5.2.2.5. Others
      • 5.2.3. Global Heatstroke Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Heatstroke Treatment by: End-users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Homecare
        • 5.2.4.3. Specialty Clinics
      • 5.2.5. Global Heatstroke Treatment by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacy
        • 5.2.5.2. Retail Pharmacy
        • 5.2.5.3. Online Pharmacy
      • 5.2.6. Global Heatstroke Treatment by: Diagnosis (Value)
        • 5.2.6.1. Rectal Temperature
        • 5.2.6.2. Blood Test
        • 5.2.6.3. Urine Test
        • 5.2.6.4. Muscle Function Test
        • 5.2.6.5. Others
      • 5.2.7. Global Heatstroke Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Heatstroke Treatment (Price)
      • 5.3.1. Global Heatstroke Treatment by: Type (Price)
  • 6. Heatstroke Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mankind Pharma (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eagle Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medisim (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson Services, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Heatstroke Treatment Sale, by Type, Drugs, Route of Administration, End-users, Distribution Channel, Diagnosis and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Heatstroke Treatment (Value)
      • 7.2.1. Global Heatstroke Treatment by: Type (Value)
        • 7.2.1.1. Exertional Heat Stroke
        • 7.2.1.2. Non-Exertional Heat Stroke
      • 7.2.2. Global Heatstroke Treatment by: Drugs (Value)
        • 7.2.2.1. Dantrolene
        • 7.2.2.2. Midazolam
        • 7.2.2.3. Clonidine
        • 7.2.2.4. Meperidine
        • 7.2.2.5. Others
      • 7.2.3. Global Heatstroke Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Heatstroke Treatment by: End-users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Homecare
        • 7.2.4.3. Specialty Clinics
      • 7.2.5. Global Heatstroke Treatment by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacy
        • 7.2.5.2. Retail Pharmacy
        • 7.2.5.3. Online Pharmacy
      • 7.2.6. Global Heatstroke Treatment by: Diagnosis (Value)
        • 7.2.6.1. Rectal Temperature
        • 7.2.6.2. Blood Test
        • 7.2.6.3. Urine Test
        • 7.2.6.4. Muscle Function Test
        • 7.2.6.5. Others
      • 7.2.7. Global Heatstroke Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Heatstroke Treatment (Price)
      • 7.3.1. Global Heatstroke Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Heatstroke Treatment: by Type(USD Million)
  • Table 2. Heatstroke Treatment Exertional Heat Stroke , by Region USD Million (2018-2023)
  • Table 3. Heatstroke Treatment Non-Exertional Heat Stroke , by Region USD Million (2018-2023)
  • Table 4. Heatstroke Treatment: by Drugs(USD Million)
  • Table 5. Heatstroke Treatment Dantrolene , by Region USD Million (2018-2023)
  • Table 6. Heatstroke Treatment Midazolam , by Region USD Million (2018-2023)
  • Table 7. Heatstroke Treatment Clonidine , by Region USD Million (2018-2023)
  • Table 8. Heatstroke Treatment Meperidine , by Region USD Million (2018-2023)
  • Table 9. Heatstroke Treatment Others , by Region USD Million (2018-2023)
  • Table 10. Heatstroke Treatment: by Route of Administration(USD Million)
  • Table 11. Heatstroke Treatment Oral , by Region USD Million (2018-2023)
  • Table 12. Heatstroke Treatment Parenteral , by Region USD Million (2018-2023)
  • Table 13. Heatstroke Treatment: by End-users(USD Million)
  • Table 14. Heatstroke Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 15. Heatstroke Treatment Homecare , by Region USD Million (2018-2023)
  • Table 16. Heatstroke Treatment Specialty Clinics , by Region USD Million (2018-2023)
  • Table 17. Heatstroke Treatment: by Distribution Channel(USD Million)
  • Table 18. Heatstroke Treatment Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 19. Heatstroke Treatment Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 20. Heatstroke Treatment Online Pharmacy , by Region USD Million (2018-2023)
  • Table 21. Heatstroke Treatment: by Diagnosis(USD Million)
  • Table 22. Heatstroke Treatment Rectal Temperature , by Region USD Million (2018-2023)
  • Table 23. Heatstroke Treatment Blood Test , by Region USD Million (2018-2023)
  • Table 24. Heatstroke Treatment Urine Test , by Region USD Million (2018-2023)
  • Table 25. Heatstroke Treatment Muscle Function Test , by Region USD Million (2018-2023)
  • Table 26. Heatstroke Treatment Others , by Region USD Million (2018-2023)
  • Table 27. South America Heatstroke Treatment, by Country USD Million (2018-2023)
  • Table 28. South America Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 29. South America Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 30. South America Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 31. South America Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 32. South America Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 33. South America Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 34. Brazil Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 35. Brazil Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 36. Brazil Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 37. Brazil Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 38. Brazil Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 39. Brazil Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 40. Argentina Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 41. Argentina Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 42. Argentina Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 43. Argentina Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 44. Argentina Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 45. Argentina Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 46. Rest of South America Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 47. Rest of South America Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 48. Rest of South America Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 49. Rest of South America Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 50. Rest of South America Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 51. Rest of South America Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 52. Asia Pacific Heatstroke Treatment, by Country USD Million (2018-2023)
  • Table 53. Asia Pacific Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 54. Asia Pacific Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 55. Asia Pacific Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 56. Asia Pacific Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 57. Asia Pacific Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 58. Asia Pacific Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 59. China Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 60. China Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 61. China Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 62. China Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 63. China Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 64. China Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 65. Japan Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 66. Japan Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 67. Japan Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 68. Japan Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 69. Japan Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 70. Japan Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 71. India Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 72. India Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 73. India Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 74. India Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 75. India Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 76. India Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 77. South Korea Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 78. South Korea Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 79. South Korea Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 80. South Korea Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 81. South Korea Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 82. South Korea Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 83. Taiwan Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 84. Taiwan Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 85. Taiwan Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 86. Taiwan Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 87. Taiwan Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 88. Taiwan Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 89. Australia Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 90. Australia Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 91. Australia Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 92. Australia Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 93. Australia Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 94. Australia Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 99. Rest of Asia-Pacific Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 100. Rest of Asia-Pacific Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 101. Europe Heatstroke Treatment, by Country USD Million (2018-2023)
  • Table 102. Europe Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 103. Europe Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 104. Europe Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 105. Europe Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 106. Europe Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 107. Europe Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 108. Germany Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 109. Germany Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 110. Germany Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 111. Germany Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 112. Germany Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 113. Germany Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 114. France Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 115. France Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 116. France Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 117. France Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 118. France Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 119. France Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 120. Italy Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 121. Italy Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 122. Italy Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 123. Italy Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 124. Italy Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 125. Italy Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 126. United Kingdom Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 127. United Kingdom Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 128. United Kingdom Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 129. United Kingdom Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 130. United Kingdom Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 131. United Kingdom Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 132. Netherlands Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 133. Netherlands Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 134. Netherlands Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 135. Netherlands Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 136. Netherlands Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 137. Netherlands Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 138. Rest of Europe Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 139. Rest of Europe Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 140. Rest of Europe Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 141. Rest of Europe Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 142. Rest of Europe Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 143. Rest of Europe Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 144. MEA Heatstroke Treatment, by Country USD Million (2018-2023)
  • Table 145. MEA Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 146. MEA Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 147. MEA Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 148. MEA Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 149. MEA Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 150. MEA Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 151. Middle East Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 152. Middle East Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 153. Middle East Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 154. Middle East Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 155. Middle East Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 156. Middle East Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 157. Africa Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 158. Africa Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 159. Africa Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 160. Africa Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 161. Africa Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 162. Africa Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 163. North America Heatstroke Treatment, by Country USD Million (2018-2023)
  • Table 164. North America Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 165. North America Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 166. North America Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 167. North America Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 168. North America Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 169. North America Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 170. United States Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 171. United States Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 172. United States Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 173. United States Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 174. United States Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 175. United States Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 176. Canada Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 177. Canada Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 178. Canada Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 179. Canada Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 180. Canada Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 181. Canada Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 182. Mexico Heatstroke Treatment, by Type USD Million (2018-2023)
  • Table 183. Mexico Heatstroke Treatment, by Drugs USD Million (2018-2023)
  • Table 184. Mexico Heatstroke Treatment, by Route of Administration USD Million (2018-2023)
  • Table 185. Mexico Heatstroke Treatment, by End-users USD Million (2018-2023)
  • Table 186. Mexico Heatstroke Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 187. Mexico Heatstroke Treatment, by Diagnosis USD Million (2018-2023)
  • Table 188. Heatstroke Treatment: by Type(USD/Units)
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Heatstroke Treatment: by Type(USD Million)
  • Table 200. Heatstroke Treatment Exertional Heat Stroke , by Region USD Million (2024-2029)
  • Table 201. Heatstroke Treatment Non-Exertional Heat Stroke , by Region USD Million (2024-2029)
  • Table 202. Heatstroke Treatment: by Drugs(USD Million)
  • Table 203. Heatstroke Treatment Dantrolene , by Region USD Million (2024-2029)
  • Table 204. Heatstroke Treatment Midazolam , by Region USD Million (2024-2029)
  • Table 205. Heatstroke Treatment Clonidine , by Region USD Million (2024-2029)
  • Table 206. Heatstroke Treatment Meperidine , by Region USD Million (2024-2029)
  • Table 207. Heatstroke Treatment Others , by Region USD Million (2024-2029)
  • Table 208. Heatstroke Treatment: by Route of Administration(USD Million)
  • Table 209. Heatstroke Treatment Oral , by Region USD Million (2024-2029)
  • Table 210. Heatstroke Treatment Parenteral , by Region USD Million (2024-2029)
  • Table 211. Heatstroke Treatment: by End-users(USD Million)
  • Table 212. Heatstroke Treatment Hospitals , by Region USD Million (2024-2029)
  • Table 213. Heatstroke Treatment Homecare , by Region USD Million (2024-2029)
  • Table 214. Heatstroke Treatment Specialty Clinics , by Region USD Million (2024-2029)
  • Table 215. Heatstroke Treatment: by Distribution Channel(USD Million)
  • Table 216. Heatstroke Treatment Hospital Pharmacy , by Region USD Million (2024-2029)
  • Table 217. Heatstroke Treatment Retail Pharmacy , by Region USD Million (2024-2029)
  • Table 218. Heatstroke Treatment Online Pharmacy , by Region USD Million (2024-2029)
  • Table 219. Heatstroke Treatment: by Diagnosis(USD Million)
  • Table 220. Heatstroke Treatment Rectal Temperature , by Region USD Million (2024-2029)
  • Table 221. Heatstroke Treatment Blood Test , by Region USD Million (2024-2029)
  • Table 222. Heatstroke Treatment Urine Test , by Region USD Million (2024-2029)
  • Table 223. Heatstroke Treatment Muscle Function Test , by Region USD Million (2024-2029)
  • Table 224. Heatstroke Treatment Others , by Region USD Million (2024-2029)
  • Table 225. South America Heatstroke Treatment, by Country USD Million (2024-2029)
  • Table 226. South America Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 227. South America Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 228. South America Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 229. South America Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 230. South America Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 231. South America Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 232. Brazil Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 233. Brazil Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 234. Brazil Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 235. Brazil Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 236. Brazil Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 237. Brazil Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 238. Argentina Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 239. Argentina Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 240. Argentina Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 241. Argentina Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 242. Argentina Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 243. Argentina Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 244. Rest of South America Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 245. Rest of South America Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 246. Rest of South America Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 247. Rest of South America Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 248. Rest of South America Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 249. Rest of South America Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 250. Asia Pacific Heatstroke Treatment, by Country USD Million (2024-2029)
  • Table 251. Asia Pacific Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 252. Asia Pacific Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 253. Asia Pacific Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 254. Asia Pacific Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 255. Asia Pacific Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 256. Asia Pacific Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 257. China Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 258. China Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 259. China Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 260. China Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 261. China Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 262. China Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 263. Japan Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 264. Japan Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 265. Japan Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 266. Japan Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 267. Japan Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 268. Japan Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 269. India Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 270. India Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 271. India Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 272. India Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 273. India Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 274. India Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 275. South Korea Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 276. South Korea Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 277. South Korea Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 278. South Korea Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 279. South Korea Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 280. South Korea Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 281. Taiwan Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 282. Taiwan Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 283. Taiwan Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 284. Taiwan Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 285. Taiwan Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 286. Taiwan Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 287. Australia Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 288. Australia Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 289. Australia Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 290. Australia Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 291. Australia Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 292. Australia Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 293. Rest of Asia-Pacific Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 294. Rest of Asia-Pacific Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 295. Rest of Asia-Pacific Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 296. Rest of Asia-Pacific Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 297. Rest of Asia-Pacific Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 298. Rest of Asia-Pacific Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 299. Europe Heatstroke Treatment, by Country USD Million (2024-2029)
  • Table 300. Europe Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 301. Europe Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 302. Europe Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 303. Europe Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 304. Europe Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 305. Europe Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 306. Germany Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 307. Germany Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 308. Germany Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 309. Germany Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 310. Germany Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 311. Germany Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 312. France Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 313. France Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 314. France Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 315. France Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 316. France Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 317. France Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 318. Italy Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 319. Italy Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 320. Italy Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 321. Italy Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 322. Italy Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 323. Italy Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 324. United Kingdom Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 325. United Kingdom Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 326. United Kingdom Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 327. United Kingdom Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 328. United Kingdom Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 329. United Kingdom Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 330. Netherlands Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 331. Netherlands Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 332. Netherlands Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 333. Netherlands Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 334. Netherlands Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 335. Netherlands Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 336. Rest of Europe Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 337. Rest of Europe Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 338. Rest of Europe Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 339. Rest of Europe Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 340. Rest of Europe Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 341. Rest of Europe Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 342. MEA Heatstroke Treatment, by Country USD Million (2024-2029)
  • Table 343. MEA Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 344. MEA Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 345. MEA Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 346. MEA Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 347. MEA Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 348. MEA Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 349. Middle East Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 350. Middle East Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 351. Middle East Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 352. Middle East Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 353. Middle East Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 354. Middle East Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 355. Africa Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 356. Africa Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 357. Africa Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 358. Africa Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 359. Africa Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 360. Africa Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 361. North America Heatstroke Treatment, by Country USD Million (2024-2029)
  • Table 362. North America Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 363. North America Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 364. North America Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 365. North America Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 366. North America Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 367. North America Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 368. United States Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 369. United States Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 370. United States Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 371. United States Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 372. United States Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 373. United States Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 374. Canada Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 375. Canada Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 376. Canada Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 377. Canada Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 378. Canada Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 379. Canada Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 380. Mexico Heatstroke Treatment, by Type USD Million (2024-2029)
  • Table 381. Mexico Heatstroke Treatment, by Drugs USD Million (2024-2029)
  • Table 382. Mexico Heatstroke Treatment, by Route of Administration USD Million (2024-2029)
  • Table 383. Mexico Heatstroke Treatment, by End-users USD Million (2024-2029)
  • Table 384. Mexico Heatstroke Treatment, by Distribution Channel USD Million (2024-2029)
  • Table 385. Mexico Heatstroke Treatment, by Diagnosis USD Million (2024-2029)
  • Table 386. Heatstroke Treatment: by Type(USD/Units)
  • Table 387. Research Programs/Design for This Report
  • Table 388. Key Data Information from Secondary Sources
  • Table 389. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Heatstroke Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Heatstroke Treatment: by Drugs USD Million (2018-2023)
  • Figure 6. Global Heatstroke Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Heatstroke Treatment: by End-users USD Million (2018-2023)
  • Figure 8. Global Heatstroke Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 9. Global Heatstroke Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 10. South America Heatstroke Treatment Share (%), by Country
  • Figure 11. Asia Pacific Heatstroke Treatment Share (%), by Country
  • Figure 12. Europe Heatstroke Treatment Share (%), by Country
  • Figure 13. MEA Heatstroke Treatment Share (%), by Country
  • Figure 14. North America Heatstroke Treatment Share (%), by Country
  • Figure 15. Global Heatstroke Treatment: by Type USD/Units (2018-2023)
  • Figure 16. Global Heatstroke Treatment share by Players 2023 (%)
  • Figure 17. Global Heatstroke Treatment share by Players (Top 3) 2023(%)
  • Figure 18. Global Heatstroke Treatment share by Players (Top 5) 2023(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Mankind Pharma (India) Revenue, Net Income and Gross profit
  • Figure 21. Mankind Pharma (India) Revenue: by Geography 2023
  • Figure 22. Eagle Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eagle Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 26. Medisim (United States) Revenue, Net Income and Gross profit
  • Figure 27. Medisim (United States) Revenue: by Geography 2023
  • Figure 28. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 30. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 32. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2023
  • Figure 34. Johnson & Johnson Services, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson Services, Inc (United States) Revenue: by Geography 2023
  • Figure 36. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 37. Abbott (United States) Revenue: by Geography 2023
  • Figure 38. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 40. Global Heatstroke Treatment: by Type USD Million (2024-2029)
  • Figure 41. Global Heatstroke Treatment: by Drugs USD Million (2024-2029)
  • Figure 42. Global Heatstroke Treatment: by Route of Administration USD Million (2024-2029)
  • Figure 43. Global Heatstroke Treatment: by End-users USD Million (2024-2029)
  • Figure 44. Global Heatstroke Treatment: by Distribution Channel USD Million (2024-2029)
  • Figure 45. Global Heatstroke Treatment: by Diagnosis USD Million (2024-2029)
  • Figure 46. South America Heatstroke Treatment Share (%), by Country
  • Figure 47. Asia Pacific Heatstroke Treatment Share (%), by Country
  • Figure 48. Europe Heatstroke Treatment Share (%), by Country
  • Figure 49. MEA Heatstroke Treatment Share (%), by Country
  • Figure 50. North America Heatstroke Treatment Share (%), by Country
  • Figure 51. Global Heatstroke Treatment: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Mankind Pharma (India)
  • Eagle Pharmaceuticals, Inc. (United States)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Medisim (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Novartis International AG (Switzerland)
  • Daiichi Sankyo Company, Limited (Japan)
  • Johnson & Johnson Services, Inc (United States)
  • Abbott (United States)
  • AstraZeneca (United Kingdom)
Additional players considered in the study are as follows:
ALLERGAN (Ireland) , Sun Pharmaceutical Industries Ltd (India)
Select User Access Type

Key Highlights of Report


Jan 2024 240 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Heatstroke Treatment Market Quantitative research analysis
Global Heatstroke Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Mankind Pharma (India), Eagle Pharmaceuticals, Inc. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Medisim (United States), Takeda Pharmaceutical Company Limited (Japan), Novartis International AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services, Inc (United States), Abbott (United States) and AstraZeneca (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Number of Online Pharmacies " is seen as one of major influencing trends for Heatstroke Treatment Market during projected period 2023-2029.
The Heatstroke Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Heatstroke Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Circle Acute Ischemic Stroke Comprehensive Study by Type (Thrombotic Ischemic Stroke, Embolic Ischemic Stroke), Treatment (Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Thera...
$ 3750
Parasitic Diseases Therapeutic Comprehensive Study by Type (Antiprotozoal Therapeutics, Anthelminthic Therapeutics, Scabicides and Pediculicides Therapeutics), Application (Hospitals, Clinics, Homeca...
$ 3650
Cold Sore Treatment Comprehensive Study by Type (Non-Pharmacological Treatment, Pharmacological Treatment), Application (Hospitals, Homecare, Specialty Clinics, Others), Drug Type (Antiviral Ointment...
$ 3750
Superficial Radiation Therapy System Comprehensive Study by Type (External Beam Superficial Radiotherapy, Internal Superficial Radiotherapy), Application (Hospitals, Ambulatory Surgical Centers, Canc...
$ 3750
Meniere’s disease drug Comprehensive Study by Type (Classic, Vestibular, Bilateral), Application (Hospitals, Homecare, Specialty Clinics, Others), Drug Type (Meclizine, Diazepam, Prochlorperazine, Hy...
$ 3750
Biopuncture Treatment Comprehensive Study by Type (Homeopathic medicines, Vitamins and minerals, Plant extracts), Application (Gynecological Disorders, Psychological Disorders, Pain Syndrome illness,...
$ 3650